Abstract
There is increasing evidence that certain probiotic strains can be useful in improving human health. The use of probiotics has received attention as a natural way of restoring bodys normal microbiota, and an alternative and inexpensive way of preventing or treating infectious diseases without side effects. The best-documented clinical application of probiotics comes from trials on the treatment of gastrointestinal infections, mainly infectious diarrhoea. The enhancement of local as well as systemic immune responses by probiotics also offers new opportunities for probiotics in preventing infections at distal mucosal surfaces, such as those in the oral cavity, respiratory and urogenital tracts. The underlying mechanisms of probiotics are still unclear, but may include strengthening of the non-immunological gut barrier, interference with pathogen adhesion and growth inhibition, and the enhancement of the local mucosal immune system in the gut, as well as of the systemic immune response.
Keywords: Probiotics, Lactobacillus, Bifidobacterium, gastrointestinal, oral, respiratory, urogenital, infection
Current Pharmaceutical Design
Title: Probiotics in Intestinal and Non-Intestinal Infectious Diseases – Clinical Evidence
Volume: 14 Issue: 14
Author(s): K. Hatakka and M. Saxelin
Affiliation:
Keywords: Probiotics, Lactobacillus, Bifidobacterium, gastrointestinal, oral, respiratory, urogenital, infection
Abstract: There is increasing evidence that certain probiotic strains can be useful in improving human health. The use of probiotics has received attention as a natural way of restoring bodys normal microbiota, and an alternative and inexpensive way of preventing or treating infectious diseases without side effects. The best-documented clinical application of probiotics comes from trials on the treatment of gastrointestinal infections, mainly infectious diarrhoea. The enhancement of local as well as systemic immune responses by probiotics also offers new opportunities for probiotics in preventing infections at distal mucosal surfaces, such as those in the oral cavity, respiratory and urogenital tracts. The underlying mechanisms of probiotics are still unclear, but may include strengthening of the non-immunological gut barrier, interference with pathogen adhesion and growth inhibition, and the enhancement of the local mucosal immune system in the gut, as well as of the systemic immune response.
Export Options
About this article
Cite this article as:
Hatakka K. and Saxelin M., Probiotics in Intestinal and Non-Intestinal Infectious Diseases – Clinical Evidence, Current Pharmaceutical Design 2008; 14 (14) . https://dx.doi.org/10.2174/138161208784480162
DOI https://dx.doi.org/10.2174/138161208784480162 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Antimicrobial Peptides and Peptidomimetics - Potent Therapeutic Allies for Staphylococcal Infections
Current Pharmaceutical Design Antimicrobial Development in the Era of Emerging Resistance
Mini-Reviews in Medicinal Chemistry Pneumococcal Infections at Hajj: Current Knowledge Gaps
Infectious Disorders - Drug Targets HtrA Protease Family as Therapeutic Targets
Current Pharmaceutical Design Comparative Time-Kill Study of Doxycycline, Tigecycline, Cefazolin and Vancomycin Against Several Clones of Staphylococcus aureus
Current Clinical Pharmacology Cardiovascular Diseases in Pregnancy - A Brief Overview
Current Cardiology Reviews Indications of Anti-Inflammatory Drugs in Cardiac Diseases
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry The Role of Universal Stress Proteins in Bacterial Infections
Current Medicinal Chemistry Biofilms: An Extra Hurdle for Effective Antimicrobial Therapy
Current Pharmaceutical Design Chemistry and Pharmacology of Natural Catechins from <i>Camellia sinensis</i> as Anti-MRSA Agents
Current Topics in Medicinal Chemistry Early Postoperative Bleeding in Polytrauma Patients Treated with Fondaparinux: Literature Review and Institutional Experience
Current Vascular Pharmacology Prokaryotic Substrate-Binding Proteins as Targets for Antimicrobial Therapies
Current Drug Targets Thoracic Aortic Aneurysm: Blood Pressure and Inflammation as Key Factors in the Development of Aneurysm Dissection
Current Pharmaceutical Design Small Molecule Inhibitors Limit Endothelial Cell Invasion by Staphylococcus aureus
Current Pharmaceutical Biotechnology Pediatric Heart Failure in the Developing World
Reviews on Recent Clinical Trials Emergence of Methicillin-Resistant Staphylococcus aureus (MRSA) as a Public-Health Threat and Future Directions of Antibiotic Therapy for MRSA Infections
Anti-Infective Agents Methylene Blue and Vasoplegia: Who, When, and How?
Mini-Reviews in Medicinal Chemistry Synthesis and Antimicrobial Evaluation of (Z)-5-((3-phenyl-1H-pyrazol-4- yl)methylene)-2-thioxothiazolidin-4-one Derivatives
Medicinal Chemistry Plant-Derived Products as Antibacterial and Antifungal Agents in Human Health Care
Current Medicinal Chemistry Oral Factor Xa (FXa) Inhibitors for Treatment of Heparin-induced Thrombocytopenia (HIT)
Current Drug Therapy